Grundlæggende statistik
| CIK | 1836295 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to RetinalGenix Technologies Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A AMENDMENT NO. |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-258528 RETINALGENIX TECHNOLOGIES INC. |
|
| August 14, 2025 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 333-258528 CUSIP NUMBER 76133Y105 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Repo |
|
| June 23, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 As filed with the Securities and Exchange Commission on June 20, 2025 Registration Statement No. |
|
| June 23, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 As filed with the Securities and Exchange Commission on June 20, 2025 Registration Statement No. |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 As filed with the Securities and Exchange Commission on June 20, 2025 Registration Statement No. |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 As filed with the Securities and Exchange Commission on June 20, 2025 Registration Statement No. |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-258528 RETINALGENIX TECHNOLOGIES INC. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-258528 RETINALGENIX TECHNOLOGIES INC |
|
| March 31, 2025 |
Exhibit 4.2 NEITHER THIS WARRANT NOR THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY OTHER SECURITIES LAWS (THE “ACTS”). NEITHER THIS WARRANT NOR THE SHARES OF COMMON STOCK PURCHASABLE HEREUNDER MAY BE SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| March 31, 2025 |
Exhibit 19.1 RETINALGENIX TECHNOLOGIES, INC. Insider Trading Policy 1. Purpose. Both the Securities and Exchange Commission (the “SEC”) and Congress are very concerned about maintaining the fairness and integrity of the U.S. capital markets. The securities laws are continually reviewed and amended to prevent people from taking advantage of “inside information” and to increase the punishment for th |
|
| February 20, 2025 |
Exhibit 10.1 AMENDMENT TO PRE-FUNDED COMMON STOCK PURCHASE WARRANT This Amendment (this “Amendment”), effective as of the 19th day of February, 2025, to the PRE-FUNDED COMMON STOCK PURCHASE WARRANT, dated December 27, 2021 (the “Warrant”), issued to Sanovas Ophthalmology, LLC or its assigns (the “Holder”) by RetinalGenix Technologies, Inc. (the “Company”). WHEREAS, the Company and Holder desire to |
|
| February 20, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 19, 2025 RETINALGENIX TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 333-258528 82-3936890 (State or other jurisdiction of incorporation) (C |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-258528 RETINALGENIX TECHNOLOGIES INC. |
|
| November 13, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 333-258528 CUSIP NUMBER 76133Y105 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-258528 RETINALGENIX TECHNOLOGIES INC. |
|
| August 14, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 333-258528 CUSIP NUMBER 76133Y105 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Repo |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-258528 RETINALGENIX TECHNOLOGIES INC. |
|
| May 16, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 333-258528 CUSIP NUMBER 76133Y105 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Rep |
|
| May 8, 2024 |
As filed with the Securities and Exchange Commission on May 7, 2024 As filed with the Securities and Exchange Commission on May 7, 2024 Registration Statement No. |
|
| May 8, 2024 |
As filed with the Securities and Exchange Commission on May 7, 2024 As filed with the Securities and Exchange Commission on May 7, 2024 Registration Statement No. |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 2, 2024 RETINALGENIX TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 333-258528 82-3936890 (State or other jurisdiction of incorporation) (Commi |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-258528 RETINALGENIX TECHNOLOGIES IN |
|
| April 1, 2024 |
Exhibit 21.1 None Subsidiaries of the Registrant DNA/GPS Inc., a Delaware corporation |
|
| April 1, 2024 |
Exhibit 4.1 DESCRIPTION OF SECURITIES RetinalGenix Technologies Inc. (the “Company,” “we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, which is our common stock, $0.0001 par value (the “common stock”). The following description is only a summary. You should also refer to our amended and restated certificate of incorpo |
|
| February 8, 2024 |
February 8, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 8, 2024 |
February 8, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 6, 2024 |
As filed with the Securities and Exchange Commission on February 6, 2024 As filed with the Securities and Exchange Commission on February 6, 2024 Registration Statement No. |
|
| January 18, 2024 |
As filed with the Securities and Exchange Commission on January 17, 2024 As filed with the Securities and Exchange Commission on January 17, 2024 Registration Statement No. |
|
| January 17, 2024 |
Schedule A Registration Statement 333-258528 January 17, 2024 VIA ELECTRONIC MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 29, 2023 |
As filed with the Securities and Exchange Commission on December 29, 2023 As filed with the Securities and Exchange Commission on December 29, 2023 Registration Statement No. |
|
| December 29, 2023 |
As filed with the Securities and Exchange Commission on December 29, 2023 As filed with the Securities and Exchange Commission on December 29, 2023 Registration Statement No. |
|
| December 29, 2023 |
December 28, 2023 VIA ELECTRONIC MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 29, 2023 |
December 28, 2023 VIA ELECTRONIC MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 4, 2023 RETINALGENIX TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 333-258528 82-3936890 (State or other jurisdiction of incorporation) (Co |
|
| December 4, 2023 |
Exhibit 10.1 Consulting Agreement This Agreement, dated December 1, 2023, is made between RetinalGenix Technologies, Inc., a Delaware corporation (“Client”) with a principal place of business at 1450 North McDowell Boulevard, Suite 150 Petaluma, CA and TRENDZ Network, LLC (“Consultant”), with a place of business at 13460A Watsonville Road, Morgan Hill, CA. RECITALS Whereas, as part of its ongoing |
|
| December 4, 2023 |
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO Exhibit 99.1 RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO Press Release | 12/01/2023 PETALUMA, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) — RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”) today announced that it has hired Virender Ahluwalia as Interim Chief Financial Officer. The Company is an ophthalmic research and development med-device and therapeut |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 30, 2023 RETINALGENIX TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 333-258528 82-3936890 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-258528 RETINALGENIX TECHNOLOGIES INC. |
|
| November 6, 2023 |
As filed with the Securities and Exchange Commission on November 6, 2023 As filed with the Securities and Exchange Commission on November 6, 2023 Registration Statement No. |
|
| November 6, 2023 |
As filed with the Securities and Exchange Commission on November 6, 2023 As filed with the Securities and Exchange Commission on November 6, 2023 Registration Statement No. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-258528 RETINALGENIX TECHNOLOGIES INC. |
|
| June 15, 2023 |
Description of Registrant’s Securities Exhibit 4.1 DESCRIPTION OF SECURITIES RetinalGenix Technologies Inc. (the “Company,” “we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, which is our common stock, $0.0001 par value (the “common stock”). The following description is only a summary. You should also refer to our amended and restated certificate of incorpo |
|
| June 15, 2023 |
Exhibit 21.1 Subsidiaries of the Registrant None |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-258528 RETINALGE |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-258528 RETINALGENIX TECHNOLOGIES INC. |
|
| May 16, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12B-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: |
|
| March 31, 2023 |
Exhibit 21.1 Subsidiaries of the Registrant None |
|
| March 31, 2023 |
Exhibit 4.1 DESCRIPTION OF SECURITIES RetinalGenix Technologies Inc. (the “Company,” “we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, which is our common stock, $0.0001 par value (the “common stock”). The following description is only a summary. You should also refer to our amended and restated certificate of incorpo |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-258528 RETINALGENIX TECHNOLOGIES INC |
|
| November 28, 2022 |
1,591,806 Shares of Common Stock Prospectus Supplement No. 2 (To Prospectus dated June 21, 2022) Filed Pursuant to Rule 424(b)(3) File No. 333-258528 1,591,806 Shares of Common Stock This prospectus supplement No. 2 amends and supplements the RetinalGenix Technologies Inc. prospectus dated June 21, 2022, which was filed with the Securities and Exchange Commission on June 21, 2022 (the ?Prospectus?), relating to the sale by the se |
|
| November 28, 2022 |
1,259,368 Shares of Common Stock Prospectus Supplement No. 2 (To Prospectus dated June 8, 2022) Filed Pursuant to Rule 424(b)(3) File No. 333-262282 1,259,368 Shares of Common Stock This prospectus supplement No. 2 amends and supplements the RetinalGenix Technologies Inc. prospectus dated June 8, 2022, which was filed with the Securities and Exchange Commission on June 6, 2022 (the ?Prospectus?), relating to the sale by the selli |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-258528 RETINALGENIX TECHNOLOGIES INC. |
|
| November 15, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12B-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: September 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q For the Transition Period End |
|
| September 7, 2022 |
1,591,806 Shares of Common Stock 424B3 1 form424b3.htm Prospectus Supplement No. 1 (To Prospectus dated June 21, 2022) Filed Pursuant to Rule 424(b)(3) File No. 333-258528 1,591,806 Shares of Common Stock This prospectus supplement No. 1 amends and supplements the RetinalGenix Technologies Inc. prospectus dated June 21, 2022, which was filed with the Securities and Exchange Commission on June 21, 2022 (the “Prospectus”), relating |
|
| September 7, 2022 |
1,259,368 Shares of Common Stock Prospectus Supplement No. 1 (To Prospectus dated June 8, 2022) Filed Pursuant to Rule 424(b)(3) File No. 333-262282 1,259,368 Shares of Common Stock This prospectus supplement No. 1 amends and supplements the RetinalGenix Technologies Inc. prospectus dated June 8, 2022, which was filed with the Securities and Exchange Commission on June 6, 2022 (the ?Prospectus?), relating to the sale by the selli |
|
| August 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-258528 RETINALGENIX TECHNOLOGIES INC. |
|
| August 15, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12B-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: June 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q For the Transition Period Ended: N |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 25, 2022 RETINALGENIX TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 333-258528 82-3936890 (State or other jurisdiction of incorporation) (Commi |
|
| July 7, 2022 |
Exhibit 10.1 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the ?Agreement?) is dated as of July 5, 2022, by and among RETINALGENIX TECHNOLOGIES, INC., a Delaware corporation (?Parent?), DNA/GPS INC., a Delaware corporation (?Company?), and LAWRENCE PERICH, an individual (the ?Stockholder?). Certain capitalized terms used in this Agreement are defined in Exhibit A. WHEREAS: A. The Stockholder is the |
|
| July 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 5, 2022 RETINALGENIX TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 333-258528 82-3936890 (State or other jurisdiction of incorporation) (Commis |
|
| July 7, 2022 |
EX-99.1 3 ex99-1.htm Exhibit 99.1 RETINALGENIX TECHNOLOGIES, INC. ACQUIRES DNA/GPS INC. Acquisition of DNA-Based “GPS” Genetic Testing Combines with RTGN’s High Resolution Retinal Imaging Technologies Seeks to Revolutionize Diagnosis of Systemic Diseases PETALUMA, Calif., July 6, 2022 /PR NEWSWIRE/ – RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), announced today t |
|
| June 21, 2022 |
As filed with the Securities and Exchange Commission on June 17, 2022 As filed with the Securities and Exchange Commission on June 17, 2022 Registration Statement No. |
|
| June 21, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) RetinalGenix Technologies Inc. |
|
| June 21, 2022 |
AW 1 formaw.htm June 17, 2022 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Laura Crotty Phone: (202) 394-0334 Re: RetinalGenix Technologies Inc. Application for Withdrawal on Form AW pursuant to Rule 477 of the Securities Act of 1933, as amended, of Post-Effective Amendment No. 2 to the Registration Statement on Form S-1 Ladies and Gentlemen: Pu |
|
| June 13, 2022 |
As filed with the Securities and Exchange Commission on June 13, 2022 POS AM 1 formposam.htm As filed with the Securities and Exchange Commission on June 13, 2022 Registration Statement No. 333-262282 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RETINALGENIX TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 384 |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 6, 2022 As filed with the Securities and Exchange Commission on June 6, 2022 Registration Statement No. |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 6, 2022 As filed with the Securities and Exchange Commission on June 6, 2022 Registration Statement No. |
|
| June 6, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) RetinalGenix Technologies Inc. |
|
| June 6, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) RetinalGenix Technologies Inc. |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| May 16, 2022 |
Exhibit 10.1 EXCHANGE AGREEMENT This Exchange Agreement (this ?Agreement?), dated as of May 9, 2022, is made by and between RetinalGenix Technologies Inc., a Delaware corporation (the ?Company?), and Sanovas Ophthalmology, LLC as the holder of the Debt (as defined below) (the ?Holder?). WHEREAS, the Company is obligated to pay the Holder $353,432 (the ?Debt?); and WHEREAS, subject to the terms and |
|
| May 13, 2022 |
10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 3 |
|
| May 13, 2022 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”), dated as of May 9, 2022, is made by and between RetinalGenix Technologies Inc., a Delaware corporation (the “Company”), and Sanovas Ophthalmology, LLC as the holder of the Debt (as defined below) (the “Holder”). WHEREAS, the Company is obligated to pay the Holder $353,432 (the “Debt”); and WHEREAS, sub |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-258528 RETINALGENIX TECHNOLOGIES IN |
|
| April 15, 2022 |
Description of Registrant’s Securities Exhibit 4.1 DESCRIPTION OF SECURITIES Our authorized capital stock consists of 80,000,000 shares of common stock, $0.0001 par value and 40,000,000 shares of preferred stock, $0.0001 par value. We have designated 3,000,000 shares of preferred stock as Series F preferred stock. As of December 31, 2021, there were 14,282,314 shares of our common stock outstanding that were held of record by approxima |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-258528- NOTIFICATION OF LATE FILING ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form N-S |
|
| February 17, 2022 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 Termination of Option Exchange Agreement This Termination of Option Exchange Agreement (this “Termination”) is dated as of February 14, 2022 by and between RetinalGenix Technologies, Inc., a Delaware corporation (“RetinalGenix”) and Diopsys, Inc., a Delaware corporation (“Diopsys”). RetinalGenix and Diopsys are each sometimes referred to herein as a “Party” and co |
|
| February 17, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 14, 2022 RETINALGENIX TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 333-258528 82-3936890 (State or other jurisdiction of incorporation) (C |
|
| February 1, 2022 |
1,259,368 Shares of Common Stock 424B3 1 form424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-262282 PROSPECTUS 1,259,368 Shares of Common Stock This prospectus relates to the sale by the selling stockholders named in this prospectus (the “Selling Stockholders”) of RetinalGenix Technologies Inc. (the “Company”) of 1,259,368 shares of common stock, par value $0.0001 per share (the “Resale Shares”). We will not recei |
|
| January 27, 2022 |
CORRESP 1 filename1.htm RetinalGenix Technologies Inc. 1450 North McDowell Boulevard, Suite 150 Petaluma, CA 94954 (415) 578-9583 January 27, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Celeste Murphy Re: RetinalGenix Technologies Inc. Registration Statement on Form S-1 File No. 333-262282 Ladies and Gentlemen: |
|
| January 26, 2022 |
RETINALGENIX TECHNOLOGIES INC. 1450 North McDowell Boulevard, Suite 150 Petaluma, CA 94954 CORRESP 1 filename1.htm RETINALGENIX TECHNOLOGIES INC. 1450 North McDowell Boulevard, Suite 150 Petaluma, CA 94954 January 26, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Chris Edwards Celeste Murphy Re: RetinalGenix Technologies Inc. Registration Statement on Form S-1 Filed January 21, 2022 File No. 333-262282 Dear Ladies and G |
|
| January 26, 2022 |
As filed with the Securities and Exchange Commission on January 26, 2022 As filed with the Securities and Exchange Commission on January 26, 2022 Registration Statement No. |
|
| January 21, 2022 |
As filed with the Securities and Exchange Commission on January 21, 2022 Registration Statement No. |
|
| January 21, 2022 |
RETINALGENIX TECHNOLOGIES INC. 424B3 1 form424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-258528 Prospectus Supplement No. 1 Dated January 21, 2022 (To Prospectus Dated October 7, 2021) RETINALGENIX TECHNOLOGIES INC. This prospectus supplement (“Supplement”) modifies, supersedes and supplements information contained in, and should be read in conjunction with, that certain prospectus (“Prospectus”), dated Octobe |
|
| December 30, 2021 |
Pre-funded Warrant dated December 27, 2021 EX-10.2 3 ex10-2.htm Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT T |
|
| December 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 27, 2021 RETINALGENIX TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 333-258528 82-3936890 (State or other jurisdiction of incorporation) (C |
|
| December 30, 2021 |
Exchange Agreement by and between the Company and Sanovas Ophthalmology, LLC dated December 27, 2021 Exhibit 10.1 EXCHANGE AGREEMENT This Exchange Agreement (this ?Agreement?), dated as of December 27, 2021, is made by and between RetinalGenix Technologies Inc., a Delaware corporation (the ?Company?), and Sanovas Ophthalmology, LLC as the holder of the Exchange Securities (as defined below) (the ?Holder?). WHEREAS, the Holder holds 28,014,540 shares of the Company?s common stock, (the ?Exchange S |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-258528 RETINALGENIX TECHNOLOGIES INC. |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: September 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q For the Transition Pe |
|
| October 8, 2021 |
1,591,806 Shares of Common Stock 424B3 1 form424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-258528 PROSPECTUS 1,591,806 Shares of Common Stock This prospectus relates to the sale by the selling stockholders named in this prospectus (the “Selling Stockholders”) of RetinalGenix Technologies Inc. (the “Company”) of 1,591,806 shares of common stock, par value $0.0001 per share, including 1,389,906 outstanding shares |
|
| October 5, 2021 |
CORRESP 1 filename1.htm RetinalGenix Technologies Inc. 1450 North McDowell Boulevard, Suite 150 Petaluma, CA 94954 (415) 578-9583 October 5, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius Re: RetinalGenix Technologies Inc. Registration Statement on Form S-1 File No. 333-258528 Ladies and Gentlemen: Pursuant to Rule |
|
| October 1, 2021 |
As filed with the Securities and Exchange Commission on October 1, 2021 S-1/A 1 forms-1a.htm As filed with the Securities and Exchange Commission on October 1, 2021 Registration Statement No. 333-258528 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RETINALGENIX TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 3841 82-3936890 (S |
|
| August 5, 2021 |
Exhibit 10.2 RETINALGENIX TECHNOLOGIES INC. 2017 EQUITY INCENTIVE PLAN [as of December 1, 2017] TABLE OF CONTENTS Page Article 1. Effective Date, Objectives and Duration 5 1.1 Effective Date of the Plan 5 1.2 Objectives of the Plan 5 1.3 Duration of the Plan 5 Article 2. Definitions 5 2.1 ?Affiliate? 5 2.2 ?Award? 5 2.3 ?Award Agreement? 5 2.4 ?Board? 6 2.5 ?Cause? 6 2.6 ?Code? 6 2.7 ?Committee? 6 |
|
| August 5, 2021 |
Exhibit 10.3 AMENDED AND RESTATED MASTER SERVICES AGREEMENT THIS AMENDED AND RESTATED AGREEMENT (this ?Agreement?), is made and entered into on this 24th day of June 2021, retroactive to the 13th day of December 2019, by and between ADM Tronics Unlimited, Inc., with offices located at 224S Pegasus Ave., Northvale, NJ 07647 (?ADMT?) and RetinalGenix Technologies Inc., with offices located at 1450 N |
|
| August 5, 2021 |
Exhibit 10.4 [*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUBLICENSE AGREEMENT THIS AGREEMENT is entered into this 24th day of June, 2021 (the ?Effective Date?), by and between Sanovas Ophthalmology LLC, a Nevada limited liability company having its principal office at |
|
| August 5, 2021 |
RETINALGENIX TECHNOLOGIES INC. 1450 North McDowell Boulevard, Suite 150 Petaluma, CA 94954 CORRESP 1 filename1.htm RETINALGENIX TECHNOLOGIES INC. 1450 North McDowell Boulevard, Suite 150 Petaluma, CA 94954 August 5, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Dillon Hagius Ada D. Sarmento Sasha Parikh Al Pavot Re: RetinalGenix Technologies Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted June |
|
| August 5, 2021 |
Exhibit 3.1 |
|
| August 5, 2021 |
Exhibit 10.1 OPTION EXCHANGE AGREEMENT This OPTION EXCHANGE AGREEMENT, dated as of October 8, 2019 (this ?Agreement?), by and between RETINALGENIX TECHNOLOGIES, INC., a Delaware corporation having an address of P.O. 2129 San Rafael, California 94912 (?RG?) and DIOPSYS, INC., a Delaware corporation having an address at 16 Chapin Road, Suite 911-912, Pine Brook, New Jersey 07058 (?DIOPSYS?). For pur |
|
| August 5, 2021 |
EX-3.2 3 ex3-2.htm Exhibit 3.2 BYLAWS OF RETINALGENIX TECHNOLOGIES INC. (a Delaware corporation) as of December 1, 2017 TABLE OF CONTENTS Page ARTICLE I MEETINGS OF STOCKHOLDERS 1 Section 1. Place of Meetings. 1 Section 2. Annual Meeting. 1 Section 3. Special Meetings. 1 Section 4. Record Date. 1 Section 5. Notice of Meetings; Waiver. 2 Section 6. List of Stockholders. 4 Section 7. Quorum; Manner |
|
| August 5, 2021 |
As filed with the Securities and Exchange Commission on August 5, 2021 Registration Statement No. |
|
| June 28, 2021 |
Exhibit 10.1 OPTION EXCHANGE AGREEMENT This OPTION EXCHANGE AGREEMENT, dated as of October 8, 2019 (this ?Agreement?), by and between RETINALGENIX TECHNOLOGIES, INC., a Delaware corporation having an address of P.O. 2129 San Rafael, California 94912 (?RG?) and DIOPSYS, INC., a Delaware corporation having an address at 16 Chapin Road, Suite 911-912, Pine Brook, New Jersey 07058 (?DIOPSYS?). For pur |
|
| June 28, 2021 |
RETINALGENIX TECHNOLOGIES INC. (a Delaware corporation) as of December 1, 2017 TABLE OF CONTENTS EX-3.2 3 filename3.htm Exhibit 3.2 BYLAWS OF RETINALGENIX TECHNOLOGIES INC. (a Delaware corporation) as of December 1, 2017 TABLE OF CONTENTS Page ARTICLE I MEETINGS OF STOCKHOLDERS 1 Section 1. Place of Meetings. 1 Section 2. Annual Meeting. 1 Section 3. Special Meetings. 1 Section 4. Record Date. 1 Section 5. Notice of Meetings; Waiver. 2 Section 6. List of Stockholders. 4 Section 7. Quorum; Man |
|
| June 28, 2021 |
RETINALGENIX TECHNOLOGIES INC. 2017 EQUITY INCENTIVE PLAN [as of December 1, 2017] TABLE OF CONTENTS Exhibit 10.2 RETINALGENIX TECHNOLOGIES INC. 2017 EQUITY INCENTIVE PLAN [as of December 1, 2017] TABLE OF CONTENTS Page Article 1. Effective Date, Objectives and Duration 5 1.1 Effective Date of the Plan 5 1.2 Objectives of the Plan 5 1.3 Duration of the Plan 5 Article 2. Definitions 5 2.1 ?Affiliate? 5 2.2 ?Award? 5 2.3 ?Award Agreement? 5 2.4 ?Board? 6 2.5 ?Cause? 6 2.6 ?Code? 6 2.7 ?Committee? 6 |
|
| June 28, 2021 |
Exhibit 3.1 |
|
| June 28, 2021 |
DRS/A 1 filename1.htm As confidentially submitted to the Securities and Exchange Commission on June 25, 2021, pursuant to the Jumpstart our Business Startups Act of 2012. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RETINALGENIX TECHNOLOGIES INC. (Exact name of registrant as |
|
| June 28, 2021 |
AMENDED AND RESTATED MASTER SERVICES Exhibit 10.3 AMENDED AND RESTATED MASTER SERVICES AGREEMENT THIS AMENDED AND RESTATED AGREEMENT (this ?Agreement?), is made and entered into on this 24th day of June 2021, retroactive to the 13th day of December 2019, by and between ADM Tronics Unlimited, Inc., with offices located at 224S Pegasus Ave., Northvale, NJ 07647 (?ADMT?) and RetinalGenix Technologies Inc., with offices located at 1450 N |
|
| June 28, 2021 |
Exhibit 10.4 [*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUBLICENSE AGREEMENT THIS AGREEMENT is entered into this 24th day of June, 2021 (the ?Effective Date?), by and between Sanovas Ophthalmology LLC, a Nevada limited liability company having its principal office at |
|
| June 25, 2021 |
RETINALGENIX TECHNOLOGIES INC. 1450 North McDowell Boulevard, Suite 150 Petaluma, CA 94954 RETINALGENIX TECHNOLOGIES INC. 1450 North McDowell Boulevard, Suite 150 Petaluma, CA 94954 June 25, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Dillon Hagius Ada D. Sarmento Sasha Parikh Al Pavot Re: RetinalGenix Technologies Inc. Draft Registration Statement on Form S-1 Submitted February 16, 2021 CIK No. 0001836295 Dear Ladies |
|
| February 16, 2021 |
DRS 1 filename1.htm As confidentially submitted to the Securities and Exchange Commission on February 16, 2021, pursuant to the Jumpstart our Business Startups Act of 2012. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RETINALGENIX TECHNOLOGIES INC. (Exact name of registrant a |
